Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 14, Pages 5637-5658Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm301424d
Keywords
-
Categories
Funding
- MIUR
- Ministero degli Affari Esteri, Direzione Generale per la Promozione del Sistema Paese
- Dote Ricerca: FSE, Regione Lombardia
Ask authors/readers for more resources
Rhodesain, a cathepsin L-like cysteine protease of T. brucei rhodesiense, is considered a potential target for the treatment of human African trypanosomiasis. Recent findings have confirmed that rhodesain, a lysosomal protease, is essential for parasite survival. Rhodesain is required by T. brucei to cross the blood-brain barrier, degrade host immunoglobulins, and turn over variant surface coat glycoproteins of T. brucei, which impair effective host immune responses. In this Perspective, we discuss the main classes of rhodesain inhibitors, including peptidic, peptidomimetic, and nonpeptidic structures, emphasizing those that have exhibited an optimal match between enzymatic affinity and trypanocidal profile and those for which predinical investigations are currently in progress.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available